FR22C1058I2 - Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide - Google Patents

Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide

Info

Publication number
FR22C1058I2
FR22C1058I2 FR22C1058C FR22C1058C FR22C1058I2 FR 22C1058 I2 FR22C1058 I2 FR 22C1058I2 FR 22C1058 C FR22C1058 C FR 22C1058C FR 22C1058 C FR22C1058 C FR 22C1058C FR 22C1058 I2 FR22C1058 I2 FR 22C1058I2
Authority
FR
France
Prior art keywords
imidazo
benzamide
ylmethyl
quinoline
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1058C
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1058(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR22C1058I1 publication Critical patent/FR22C1058I1/fr
Application granted granted Critical
Publication of FR22C1058I2 publication Critical patent/FR22C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR22C1058C 2014-07-25 2022-12-06 Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide Active FR22C1058I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (2)

Publication Number Publication Date
FR22C1058I1 FR22C1058I1 (fr) 2023-01-06
FR22C1058I2 true FR22C1058I2 (fr) 2023-11-17

Family

ID=53762251

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1058C Active FR22C1058I2 (fr) 2014-07-25 2022-12-06 Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3172209B1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR102581121B1 (enExample)
CN (2) CN115364061A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA202191301A1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG10201900648SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TWI724993B (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
KR102581121B1 (ko) 2014-07-25 2023-09-21 노파르티스 아게 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
IL305639B1 (en) 2016-08-10 2025-10-01 Hoffmann La Roche Medicinal products containing Akt protein kinase inhibitors
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
US20220378790A1 (en) * 2019-10-24 2022-12-01 Hanmi Pharm Co., Ltd. Pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA3264627A1 (en) 2022-08-19 2024-02-22 Mirati Therapeutics, Inc. SOLID PHARMACEUTICAL COMPOSITIONS OF ADAGRASIB
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
AU2006272760A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
SI2497470T1 (sl) * 2006-11-22 2016-02-29 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
HRP20250604T1 (hr) * 2009-11-09 2025-07-18 Wyeth Llc Formulacije tableta neratinib maleata
PE20160042A1 (es) 2010-02-25 2016-01-28 Bristol Myers Squibb Holdings Ireland Formulaciones de apixaban
US20110288107A1 (en) * 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
JP6093699B2 (ja) 2010-07-06 2017-03-08 ヤンセン ファーマシューティカ エヌ．ベー． 糖尿病のコ−セラピー治療のための製剤
IN2015DN00528A (enExample) 2012-08-16 2015-06-26 Novartis Ag
KR102581121B1 (ko) 2014-07-25 2023-09-21 노파르티스 아게 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Also Published As

Publication number Publication date
SG11201700147SA (en) 2017-02-27
ES2857523T3 (es) 2021-09-29
US20170231997A1 (en) 2017-08-17
SG10201900648SA (en) 2019-02-27
AR101286A1 (es) 2016-12-07
EA039220B1 (ru) 2021-12-20
DK3172209T3 (da) 2021-02-22
PT3172209T (pt) 2021-02-11
JP2022046659A (ja) 2022-03-23
US20190015418A1 (en) 2019-01-17
KR20230136693A (ko) 2023-09-26
EA202191301A1 (ru) 2021-11-30
EP3172209B1 (en) 2020-12-02
US20210113569A1 (en) 2021-04-22
US12208101B2 (en) 2025-01-28
CO2017000586A2 (es) 2017-06-20
EP3848376A1 (en) 2021-07-14
JP6770946B2 (ja) 2020-10-21
AU2021202500A1 (en) 2021-05-20
MX379279B (es) 2025-03-11
PL3172209T3 (pl) 2021-06-14
SI3172209T1 (sl) 2021-03-31
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
AU2018207947A1 (en) 2018-08-09
AU2015293539A1 (en) 2017-02-02
JP2017521469A (ja) 2017-08-03
KR20170039211A (ko) 2017-04-10
MX2021000595A (es) 2021-04-13
JP2020114852A (ja) 2020-07-30
US20220249498A1 (en) 2022-08-11
US20250339440A1 (en) 2025-11-06
BR112017000953A2 (pt) 2017-11-14
HUE053346T2 (hu) 2021-06-28
US10085993B2 (en) 2018-10-02
CN115364061A (zh) 2022-11-22
JP7002587B2 (ja) 2022-01-20
MY187276A (en) 2021-09-17
EP3172209A1 (en) 2017-05-31
ECSP17011672A (es) 2018-03-31
WO2016012963A1 (en) 2016-01-28
GT201700007A (es) 2018-12-18
FR22C1058I1 (fr) 2023-01-06
US10596178B2 (en) 2020-03-24
MX2017001177A (es) 2017-05-01
IL250166A0 (en) 2017-03-30
IL250166B (en) 2021-01-31
CA2954840A1 (en) 2016-01-28
TW202200148A (zh) 2022-01-01
KR102581121B1 (ko) 2023-09-21
PE20170523A1 (es) 2017-05-17
NL301208I2 (nl) 2025-03-20
NZ728089A (en) 2024-01-26
HUS2200054I1 (hu) 2023-01-28
NO2022058I1 (no) 2022-12-16
TWI724993B (zh) 2021-04-21
TW201613595A (en) 2016-04-16
CL2017000180A1 (es) 2017-09-15
EA201790259A1 (ru) 2017-06-30
PH12017500121A1 (en) 2017-05-29
AU2020200912A1 (en) 2020-02-27
JO3618B1 (ar) 2020-08-27

Similar Documents

Publication Publication Date Title
FR22C1058I2 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
HUE051067T2 (hu) N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik
IL264143B (en) Processes for preparing olaparib
HUE064612T2 (hu) Eljárás brivaracetam elõállítására
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
HUE054245T2 (hu) Immunszupresszáns formuláció
DK3310340T3 (da) Formulering med høj koncentration
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
IL266537A (en) pharmaceutical preparation
IL253570B (en) Pharmacy composition
IL250613B (en) Substituted bicyclic compounds
ZA201606075B (en) Pharmaceutical compositions of sitagliptin
IL253177A0 (en) Pharmacy preparation
FR3039396B1 (fr) Base de formulation cosmetique concentree
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
LT3230289T (lt) 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
HRP20180788T1 (hr) [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti
DK3362453T3 (da) Cykliske etherderivater af pyrazolo[1,5-a]pyrimidin-3-carboxyamid
ZA201807851B (en) Pharmaceutical formulation
GB201506755D0 (en) Novel pharmaceutical formulation
MA43166A (fr) Formulation de fviii
GB201511246D0 (en) Pharmaceutical formulation